Navigation Links
Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
Date:5/22/2013

MAPLE GROVE, Minn., May 22, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.  USL255 is specifically engineered to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available treatment options.  Upsher-Smith's New Drug Application for USL255 has been accepted for review by the U.S. Food and Drug Administration (FDA) with an anticipated target review date under the Prescription Drug User Fee Act (PDUFA) of December 2013.

(Logo: http://photos.prnewswire.com/prnh/20130520/NY17281LOGO)

In the study, USL255 demonstrated a positive treatment effect as adjunctive therapy in patients with refractory partial-onset seizures (POS) compared with placebo.  USL255 had a statistically significant reduction from baseline in weekly POS frequency during the titration plus maintenance phase compared to placebo (p<0.001).  Preliminary findings from the Phase III trial will be submitted for presentation at the 2013 Annual Meeting of the American Epilepsy Society, December 6-10 in Washington, D.C.

"We are very excited by the preliminary findings from this well-executed global trial.  Sixty-nine centers enrolled more than 200 patients to evaluate the safety and efficacy of USL255, a uniquely designed extended-release formulation of topiramate," said Steve Chung , M.D., Professor of Neurology at the Barrow Neurological Institute, Phoenix and trial investigator.  "This study provides strong evidence suggesting that once-daily USL255 may be a therapeutic option for patients suffering from partial-onset seizures."

"The successful completion of the Phase III clinical trial of USL255 marks an exciting milestone in Upsher-Smith's focused strategy to develop and deliver therapies to address central nervous system disorders," said Mark Evenstad , President and CEO of Upsher-Smith.  "Underpinning this strategy is our commitment to advancing pharmacotherapy to improve lives."

About the Trial
The Phase III (PREVAIL) trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of USL255 as adjunctive therapy in patients with refractory POS.  PREVAIL was conducted under a Special Protocol Assessment (SPA) agreement with the FDA.  More information about the trial is available at www.clinicaltrials.gov (NCT01142193). 

An open-label extension study to evaluate the safety of USL255 as adjunctive therapy in patients with refractory POS who had participated in PREVAIL is ongoing.  The open-label extension study can be found by searching NCT01191086 on www.clinicaltrials.gov.

About Epilepsy
Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions.  More than two million people in the U.S. are estimated to be affected by epilepsy with about 200,000 new cases of epilepsy diagnosed each year.1 For many people with epilepsy, medication will prevent seizures if taken regularly, but some people continue to have seizures.1  As many as two out of three patients treated for epilepsy have seizures that are refractory to therapy, either because they have incomplete control of their seizures or they experience treatment-related side effects that interfere with their quality of life.2

Upsher-Smith's Epilepsy Pipeline
Upsher-Smith's clinical development pipeline includes three investigational drugs that are being studied for the management of epilepsy.  USL255 is an investigational once-daily, extended-release topiramate for the management of epilepsy.  The pipeline also includes USL261, an investigational intranasal midazolam for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters, which is the subject of an ongoing international Phase III clinical trial (ARTEMIS1) with an open-label safety extension study.  In addition, USL260 (tonabersat) is in early clinical development as a potential first-in-class neuronal gap junction modulator.

About Upsher-Smith
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals.  Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit www.upsher-smith.com.

References

  1. Epilepsy Foundation.  Available at: http://www.epilepsyfoundation.org. Accessed May 2, 2013.
  2. Epilepsy.com. Available at http://professionals.epilepsy.com/secondary/Refractory_Seizures.html. Accessed May 2, 2013.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Introduces Newly Redesigned Corporate Website
2. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
3. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
4. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
5. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
6. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
7. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
8. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
9. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
10. SonaCare Medical Successfully Launches New Products at European Association of Urology (EAU)
11. Educating, Informing, and Successfully Preparing the Marketplace for New Bio-Pharma Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Treated at Proton Therapy Centers & Forecast" report to their offering. ... The South Korean Proton ... market size in 2016. The Untapped Proton Therapy Market for ... in 2016. Proton Therapy plays an important role in ...
(Date:3/29/2017)... , March 29, 2017  Experts in the ... monitoring devices like  Soberlink Systems  as a model ... paper, published in early 2017, concluded that remote ... in managing patient recovery." The findings ... of Addiction Medicine, detail a range of variables ...
(Date:3/29/2017)... Calif. , March 29, 2017 ... for patients as the highest standard in quality ... Krypton Vision introduces its objective Wavefront-driven refraction technologies ... subjective approach. This enables an unprecedented level of ... - exceptional vision relegated to Topgun Navy fighter ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... , ... An inventor and manicurist from Greet, S.C., wants to offer people a new way ... maintain clean and healthy feet, so I know the importance of proper foot care," he ... designed the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate ...
(Date:3/30/2017)... ... March 30, 2017 , ... This ... to President Trump expressing their support for an independent Vaccine Safety Commission. Five ... and one medical journalist, will hold a press conference at 9:00 AM ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... In the ... to 300,000 people each year develop other types of metastatic brain tumors(3). Though most ... the brain(3). As efforts focus on finding more effective treatment options, the San ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... St. Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... Often called the "Spice of Life" or "Wonder Spice", it has been used for ... extensive use in the East," says Heshelow, author of " Turmeric: How to Use ...
Breaking Medicine News(10 mins):